Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.79 |
| ▸ | RAB9A | P51151 | 6/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.79 |
| ▸ | MAPT | P10636 | 2/20 | 0.79 |
| ▸ | GLA | P06280 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | METAP2 | P50579 | 1/20 | 0.55 |
| ▸ | METAP1 | P53582 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10686239 | 0.91 | RAB9A (0.70) | NPC1RAB9AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL11924959 | 0.88 | RAB9A (1.00) | NPC1RAB9AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL30136193 | 0.84 | NPC1 (0.60) | NPC1RAB9AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL23727897 | 0.84 | NPC1 (0.60) | NPC1RAB9AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL1607268 | 0.83 | RAB9A (0.56) | NPC1RAB9AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL15113529 | 0.83 | ALDH1A1 (0.75) | NPC1RAB9AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL13774685 | 0.79 | GLA (1.00) | NPC1RAB9AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL2652484 | 0.77 | RAB9A (0.50) | NPC1RAB9AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL4948396 | 0.77 | GPR84 (0.61) | NPC1RAB9AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL2660937 | 0.77 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148413-B2 | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes | TRANSTECH PHARMA, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110082144-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-7812043-B2 | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes | TRANSTECH PHARMA, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20070027140-A1 | N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes | NOVO NORDISK A/S (DK) | 2007-02-01 | — | — | US | disclosed |
| EP-1689392-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2006-08-16 | — | — | EP | disclosed |
| EP-1549638-A1 | INDOLE-3-CARBOXAMIDES AS GLUCOKINASE (GK) ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-06 | — | — | EP | disclosed |
| WO-2005049019-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2005-06-02 | — | — | WO | disclosed |
| WO-2004031179-A1 | INDOLE-3-CARBOXAMIDES AS GLUCOKINASE (GK) ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-15 | — | — | WO | disclosed |
| US-5656648-A | TREATMENT OF PATHOLOGIES NECESSITATING STIMULATION OF CHOLECYSTOKININ-A RECEPTORS BY TOTAL OR PARTIAL AGONIST EFFECT | SANOFI (FR) | 1997-08-12 | — | — | US | disclosed |
| EP-0611766-A1 | Polysubstituted 2-amido thiazoles derivatives, process for their preparation, pharmaceutical compositions and utilization for the preparation of a medicament | SANOFI (FR) | 1994-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027140-A1 | N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes | GALK1, GCKR, GCK | NPC1 4060/4885RAB9A 4493/4885ALDH1A1 2638/4885 |
| US-20110082144-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | GCKR, GCK, GALK1 | NPC1 3131/4885RAB9A 3609/4885ALDH1A1 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.